Display options
Cite
Li P, Dorsch W, Lauffer DJ, et al. Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates. ACS Med Chem Lett. 2017;8(2):251-255doi: 10.1021/acsmedchemlett.6b00479.
Li, P., Dorsch, W., Lauffer, D. J., Bilimoria, D., Chauret, N., Court, J. J., Das, S. K., Denis, F., Mani, N., Nanthakumar, S., Nicolas, O., Rao, B. G., Ronkin, S., Selliah, S., Shawgo, R. S., Stearns, R., Tang, Q., Waal, N. D., & Green, J. (2017). Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates. ACS medicinal chemistry letters, 8(2), 251-255. https://doi.org/10.1021/acsmedchemlett.6b00479
Li, Pan, et al. "Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates." ACS medicinal chemistry letters vol. 8,2 (2017): 251-255. doi: https://doi.org/10.1021/acsmedchemlett.6b00479
Li P, Dorsch W, Lauffer DJ, Bilimoria D, Chauret N, Court JJ, Das SK, Denis F, Mani N, Nanthakumar S, Nicolas O, Rao BG, Ronkin S, Selliah S, Shawgo RS, Stearns R, Tang Q, Waal ND, Green J. Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates. ACS Med Chem Lett. 2017 Jan 31;8(2):251-255. doi: 10.1021/acsmedchemlett.6b00479. eCollection 2017 Feb 09. PMID: 28197321; PMCID: PMC5304295.
Copy Download .nbib Format: NLM
Share it on

ACS Med Chem Lett. 2017 Jan 31;8(2):251-255. doi: 10.1021/acsmedchemlett.6b00479. eCollection 2017 Feb 09.

Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates.

ACS medicinal chemistry letters

Pan Li, Warren Dorsch, David J Lauffer, Darius Bilimoria, Nathalie Chauret, John J Court, Sanjoy Kumar Das, Francois Denis, Nagraj Mani, Suganthini Nanthakumar, Olivier Nicolas, B Govinda Rao, Steven Ronkin, Subajini Selliah, Rebecca S Shawgo, Ralph Stearns, Qing Tang, Nathan D Waal, Jeremy Green

Affiliations

  1. Vertex Pharmaceuticals Incorporated , 50 Northern Avenue, Boston, Massachusetts 02210, United States.
  2. Vertex Pharmaceuticals (Canada) Incorporated , 275 Boulevard Armand Frappier, Laval, Quebec H7 V 4A7, Canada.

PMID: 28197321 PMCID: PMC5304295 DOI: 10.1021/acsmedchemlett.6b00479

Abstract

Lomibuvir (

Keywords: Lomibuvir; NS5B; antiviral activity; hepatitis C; non-nucleoside; polymerase

Conflict of interest statement

The authors declare the following competing financial interest(s): All of the authors of this manuscript are current or former employees of Vertex Pharmaceuticals.

References

  1. J Med Chem. 2012 Mar 22;55(6):2481-531 - PubMed
  2. J Virol. 2006 Jun;80(12):6146-54 - PubMed
  3. Lancet Infect Dis. 2005 Sep;5(9):558-67 - PubMed
  4. J Virol. 2001 May;75(10):4614-24 - PubMed
  5. J Virol. 2002 Dec;76(24):13088-93 - PubMed
  6. Infect Dis Ther. 2016 Sep;5(3):299-312 - PubMed
  7. J Med Chem. 2016 Jul 14;59(13):6293-302 - PubMed
  8. Nature. 2011 Jun 08;474(7350):S5-7 - PubMed
  9. J Biol Chem. 2005 May 6;280(18):18202-10 - PubMed
  10. Acc Chem Res. 2008 Jan;41(1):50-9 - PubMed
  11. Antimicrob Agents Chemother. 2006 Mar;50(3):899-909 - PubMed
  12. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3979-85 - PubMed
  13. Rev Med Virol. 2015 Jul;25(4):254-67 - PubMed
  14. J Hepatol. 2014 Nov;61(1 Suppl):S45-57 - PubMed

Publication Types